Candel to present CAN-3110 glioma data and CAN-2409 NSCLC topline OS at ASCO 2024

Candel Therapeutics, Inc.

Two abstracts accepted for ASCO 2024: CAN-3110 phase 1 (recurrent high-grade glioma, cohort C) and CAN-2409 phase 2 (NSCLC with inadequate ICI response).
CAN-3110 data: multiple injections (up to six) feasible and well tolerated in cohort C.
CAN-2409 presentation will show topline overall survival data with valacyclovir + continued ICI.
Presentations on June 1 (CAN-3110) and June 3 (CAN-2409) at ASCO in Chicago.
Full abstracts released by ASCO on May 23, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.